Silvestris F, Cafforio P, Camarda G, Tucci M, Frassanito M A, Dammacco F
Department of Biomedical Sciences and Human Oncology, University of Bari, Italy.
Int J Clin Lab Res. 1998;28(4):215-25. doi: 10.1007/s005990050048.
Recent studies have demonstrated that the expression of Fas by peripheral T cells from HIV-1+ patients is deregulated and increases the susceptibility of these cells to undergo apoptosis. Here, we show that secretion of Fas-ligand (L), the complementary agonist of Fas, is abnormally upregulated in CD4+ cells from HIV-1-infected individuals, particularly during the non-lymphopenic stages of the disease. An increase of soluble Fas-L occurred in T cell cultures from 26 patients with a number of CD4+ cells higher than 400/microliter, whereas it was almost undetectable in cultures from 21 severely lymphopenic patients (CD4+ < 200/microliter). The MTT test, cytofluorimetric analysis of cellular DNA, cytotoxicity, and proliferative assays using the Fas-transfected WC8 mouse lymphoma confirmed the cytocidal capability of T cell supernatants from non-lymphopenic patients. Double-fluorescence analysis revealed that the majority of CD4+ cells (approximately 90%) in these cultures secreted Fas-L in the presence of high intracellular gamma-interferon and low Bcl-2. In contrast, the CD8+/Fas-L+ population was comparably decreased (approximately 55%). Molecular cloning of Fas-L revealed a substantial expression of Fas-L mRNA in cells from non-lymphopenic patients compared with patients with advanced disease and healthy controls. Since CD4+ cells of Th1 phenotype are impaired during HIV-1 infection and show high cellular expression of Fas-L, it is conceivable that excess Fas-L during the early or non-lymphopenic phase of the disease increases the extent of apoptosis in these cells by the Fas/Fas-L pathway. The defective expression of the ligand in severely lymphopenic stages could be explained by exhaustion of this mechanism as the disease progresses.
近期研究表明,HIV-1阳性患者外周血T细胞Fas表达失调,增加了这些细胞发生凋亡的易感性。在此,我们发现,Fas的互补激动剂Fas配体(L)在HIV-1感染个体的CD4+细胞中异常上调,尤其是在疾病的非淋巴细胞减少阶段。26例CD4+细胞数高于400/微升患者的T细胞培养物中可溶性Fas-L增加,而21例严重淋巴细胞减少患者(CD4+<200/微升)的培养物中几乎检测不到。MTT试验、细胞DNA的细胞荧光分析、细胞毒性以及使用Fas转染的WC8小鼠淋巴瘤进行的增殖试验证实了非淋巴细胞减少患者T细胞上清液的杀细胞能力。双荧光分析显示,在这些培养物中,大多数CD4+细胞(约90%)在细胞内γ干扰素水平高且Bcl-2水平低的情况下分泌Fas-L。相比之下,CD8+/Fas-L+群体相对减少(约55%)。Fas-L的分子克隆显示,与晚期疾病患者和健康对照相比,非淋巴细胞减少患者细胞中Fas-L mRNA大量表达。由于HIV-1感染期间Th1表型的CD4+细胞受损且Fas-L细胞表达高,因此可以想象,在疾病的早期或非淋巴细胞减少阶段,过量的Fas-L通过Fas/Fas-L途径增加了这些细胞的凋亡程度。随着疾病进展,该机制耗竭可解释严重淋巴细胞减少阶段配体的表达缺陷。